Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Publication

Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Journal Paper/Review - Feb 14, 2022

Zehnder Mara, Amarov Boyko, Abrunhosa-Branquinho André N, Maiwald-Urosevic Mirjana, Mühleisen Beda, Saulite Ieva, Anzengruber Florian, Imhof Laurence, Navarini Alexander A, Cozzio Antonio, Dummer Reinhard, Dimitriou Florentia, Guenova Emmanuella

Citation

Zehnder M, Amarov B, Abrunhosa-Branquinho A, Maiwald-Urosevic M, Mühleisen B, Saulite I, Anzengruber F, Imhof L, Navarini A, Cozzio A, Dummer R, Dimitriou F, Guenova E. Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Dermatology 2022; 238:967-976.

Type

Journal Paper/Review (English)

Journal

Dermatology 2022; 238

Publication Date

Feb 14, 2022

Issn Electronic

1421-9832

Pages

967-976

Brief description/objective

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is an aggressive lymphoma variant. Anthracycline-based chemotherapy with rituximab is recommended as first-line treatment. Radiotherapy (RT) has been considered as a therapeutic option for local disease control in patients with solitary or localized lesions.